InhaleRx Limited (ASX:IRX)

Australia flag Australia · Delayed Price · Currency is AUD
0.0400
+0.0010 (2.56%)
Jun 6, 2025, 4:10 PM AEST
33.33%
Market Cap 8.54M
Revenue (ttm) 401.81K
Net Income (ttm) -1.21M
Shares Out 213.45M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 710,752
Average Volume 196,396
Open 0.0390
Previous Close 0.0390
Day's Range 0.0390 - 0.0420
52-Week Range 0.0180 - 0.0500
Beta -0.04
RSI 88.47
Earnings Date May 30, 2025

About InhaleRx

InhaleRx Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as Lifespot Health Ltd and changed its name to InhaleRx Limited in October 2021. InhaleRx Limited was incorporated in 2016 and is headquartered in Melbourne, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol IRX
Full Company Profile

Financial Performance

In 2024, InhaleRx's revenue was 401,811, a decrease of -66.63% compared to the previous year's 1.20 million. Losses were -1.21 million, -16.21% less than in 2023.

Financial Statements

News

There is no news available yet.